【兰德】2024年药品价格回扣与保险保费报告-商业市场中药品支出其他医疗成本与保费的关联分析_142页_1mb

Summary of RAND Report on Prescription Drug Prices, Rebates, and Insurance Premiums

Background

The consolidation of healthcare data under Section 204 of the Consolidated Appropriations Act of 2021 aims to provide insights into the complex relationships between prescription drug spending, insurance premiums, and patient costs. This analysis summarizes key findings across multiple dimensions of prescription drug policy challenges.

Key Findings

1. Drug Spending Trends

• Gross vs. Net Prices: Manufacturer gross prices grew at 6.9% annually (2011-2022), while net prices (after rebates) grew at 4.7%. This gap widened, suggesting higher net prices for commercial insurers compared to Medicare/Medicaid.
• Therapeutic Classes: Specialty drugs (biologics, oncology) saw disproportionate spending growth; insulin analogs showed the largest net-to-gross discount (ratio ~0.52), reflecting competition and formulary manipulation.
• Market Segments: Individual market plans exhibited the highest gross-to-net price gap, potentially due to less bargaining power compared to large group plans.

2. Premium and Benefit Design

• Cost-Sharing: Insurers increasingly used coinsurance (vs. copayments) for high-cost drugs, increasing patient exposure to list prices despite rebates.
• Premium Adjustments: Premium increases were minimal despite rising drug spending, suggesting insurers absorbed costs through benefit design changes (formulary tiers, utilization management) rather than premium hikes.

3. Rebate Mechanics

• Net Price Calculation: RXDC data revealed net prices were ~80% of gross prices (ratio 0.8 in 2020-2021). Insulin showed the highest rebating (0.52 net-to-gross), while kinase inhibitors had almost no discount (~1.0 ratio).
• PBM Margins: Limited data suggest PBMs may retain portions of rebates, creating "spread-based" contracts that obscure net savings.

Recommendations for RxDC Improvements

1. Standardized Reporting Levels: Consolidate data at consistent plan/segment/state levels to enable cross-template comparisons.
2. Submitter Identification: Institutionalize EIN reporting to clarify data ownership.
3. Plan-Sponsor Perspective: Clarify whether rebate data reflect plan or PBM margins.
4. Consistent Metrics: Append net/gross spending and out-of-pocket data to all templates.
5. Granular Drug Breakdowns: Add brand/generic/therapeutic class breakdowns for more targeted analysis.

Limitations and Future Opportunities

• RxDC Constraints: Inconsistent aggregation prevents linking premium/spending data.
• Policy Insights: Future rounds could explore links between rebates, premiums, and consumer costs; however, systematic reform is needed to untangle complex market dynamics.

Conclusion

While initial RxDC data provide valuable insights, limitations in standardization and perspective create significant challenges. Addressing these issues will allow policymakers to better understand how drug spending influences premiums, benefit design, and patient affordability.